Longitudinal Changes in IgG-Type SARS-CoV-2 Antibody Titers after COVID-19 Vaccination and a Prominent Increase in Antibody Titers When Infected after Vaccination
Vaccines · 17.04.2023 · 11 (4) · 860
DOI: 10.3390/vaccines11040860 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 17.04.2023. Verfasst von Hiroshi Kusunoki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Osaka Dental University, 8-1 Kuzuhahanazonocho, Hirakata 573-1121, Japan. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Osaka Dental University.
Abstract (Originalsprache)
Objective
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody titers level and duration of elevated levels are considered important indicators for confirming the efficacy of coronavirus disease 2019 (COVID-19) vaccines. The objective of this study was to demonstrate the changes in antibody titers after the second and third doses of the COVID-19 vaccine, and to determine the antibody titers in cases of spontaneous infection with SARS-CoV-2 after vaccination. Materials and Methods: From June 2021 to February 2023, IgG-type SARS-CoV-2 antibody titers were measured in 127 participants, including 74 outpatients and 53 members of staff, at the Osaka Dental University Hospital (64 males and 63 females, mean age 52.3 ± 19.0 years).
Results
Consistent with previous reports, the SARS-CoV-2 antibody titer decreased with time, not only after the second dose but also after the third dose of the vaccine if there was no spontaneous COVID-19 infection. We also confirmed that the third booster vaccination was effective in increasing the antibody titer. A total of 21 cases of natural infections were observed after administering two or more doses of the vaccine. Thirteen of these patients had post-infection antibody titers exceeding 40,000 AU/mL, and some cases continued to maintain antibody titers in the tens of thousands of AU/mL even after more than 6 months had passed since infection.
Conclusions
The rise in and duration of antibody titers against SARS-CoV-2 are considered important indicators for confirming the efficacy of novel COVID-19 vaccines. A longitudinal follow-up of antibody titers after vaccination in larger studies is warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Osaka Dental University, 8-1 Kuzuhahanazonocho, Hirakata 573-1121, Japan.
- Department of Laboratory Medicine, Osaka Dental University Hospital, Osaka 565-0871, Japan.
- Department of Environmental and Preventive Medicine, Hyogo Medical University, Nishinomiya 663-8501, Japan.
- Department of Health and Sports Sciences, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan.
- Faculty of Health Sciences, Osaka Dental University, Hirakata 573-1144, Japan.
Förderung
- Osaka Dental University
Zitieren
APA
Kusunoki, H., Ohkusa, M., Iida, R., Saito, A., Kawahara, M., Ekawa, K., Kato, N., Yamasaki, K., Motone, M., & Shimizu, H. (2023). Longitudinal Changes in IgG-Type SARS-CoV-2 Antibody Titers after COVID-19 Vaccination and a Prominent Increase in Antibody Titers When Infected after Vaccination. Vaccines, 11(4), 860. https://doi.org/10.3390/vaccines11040860
Vancouver
Kusunoki H, Ohkusa M, Iida R, Saito A, Kawahara M, Ekawa K, et al. Longitudinal Changes in IgG-Type SARS-CoV-2 Antibody Titers after COVID-19 Vaccination and a Prominent Increase in Antibody Titers When Infected after Vaccination. Vaccines. 2023;11(4):860. doi:10.3390/vaccines11040860
BibTeX
@article{Kusunoki2023,
author = {Kusunoki, Hiroshi and Ohkusa, Michiko and Iida, Rie and Saito, Ayumi and Kawahara, Mikio and Ekawa, Kazumi and Kato, Nozomi and Yamasaki, Keita and Motone, Masaharu and Shimizu, Hideo},
title = {Longitudinal Changes in IgG-Type SARS-CoV-2 Antibody Titers after COVID-19 Vaccination and a Prominent Increase in Antibody Titers When Infected after Vaccination},
journal = {Vaccines},
year = {2023},
volume = {11},
number = {4},
pages = {860},
doi = {10.3390/vaccines11040860}
}
EUVIMED